Chuantao Zhang

Dr. Chuantao Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JCJing Cong
Jing Cong
CZChuantao Zhang
Chuantao Zhang
SZSiyu Zhou
Siyu Zhou
JZJingjuan Zhu
Jingjuan Zhu
CLChengwei Liang
Chengwei Liang
Probiotics as medications have previously been shown to change intestinal microbial characteristics, potentially influencing cancer therapy efficacy. Patients with non-squamous non-small cell lung cancer (NS-NSCLC) treated by bevacizumab plus platinum-based chemotherapy were randomized to obtain Clostridium butyricum supplement (CBS) or receive a placebo as adjuvant therapy. Clinical efficacy and safety were assessed using progression-free survival (PFS), overall survival (OS), and adverse events (AE). Intestinal microbiota was longitudinally explored between CBS and placebo groups over time. Patients who took CBS had significantly decreased bacterial richness and abundance, as well as increased the total richness of the genus Clostridium, Bifidobacterium, and Lactobacillus compared to the placebo group (p < 0.05). Beta diversity and the interactional network of intestinal microbiota were distinctly different between CBS and placebo group. However, there were no significant variations between them in terms of microbial taxonomical taxa and alpha diversity. The potential opportunistic pathogen Shewanella was still detectable after treatment in the placebo group, while no distinguishing microbial markers were found in the CBS group. In terms of clinical efficacy, the CBS group had a significantly reduced AE compare to the placebo group (p < 0.05), although no significantly longer PFS and OS. Therefore, favorable modifications in intestinal microbiota and significant improvements in drug safety make probiotics be promising adjunctive therapeutic avenues for lung cancer treatment.

29 April 2026 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
XHXingfa Huo
Xingfa Huo
HHHelei Hou
Helei Hou
CZChuantao Zhang
Chuantao Zhang
XDXueqin Duan
Xueqin Duan
HLHongwei Lan
Hongwei Lan
XZXiaochun Zhang
Xiaochun Zhang
Chicoric acid (CA), a bioactive natural compound found in Chicory and Echinacea purpurea, exhibits antiinflammatory, antioxidant, and apoptosis-inducing pr

5 December 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
XHXiao Huang
Xiao Huang
YMYing Ma
Ying Ma
HWHuiyun Wang
Huiyun Wang
SSShanai Song
Shanai Song
TLTianjun Li
Tianjun Li
HHhelei hou
helei hou
With advances in medical technology, the diagnosis of multiple primary cancers (MPC) is becoming increasingly common. Despite significant advancements in therapeutic approaches, definitive management strategies for synchronous primary cancers are still not fully established. We report the case of a 56-year-old male smoker diagnosed with synchronous primary lung (cT2N0M0, stage IB) and base-of-tongue (cT1N2M0, stage IVA) squamous cell carcinoma (SCC), exhibiting a high PD-L1 tumor proportion score (TPS) of 90%. After multidisciplinary team evaluation, the patient received induction chemoimmunotherapy with albumin-bound paclitaxel, cisplatin, and the PD-1 inhibitor tislelizumab. Following four cycles, imaging assessments indicated a partial response (PR) in both malignancies according to RECIST 1.1. Subsequent thoracoscopic resection of the lung lesion confirmed a pathological complete response (pCR; ypT0N0). Remarkably, the base-of-tongue primary also achieved a clinical complete response (cCR), obviating the need for surgical or radiotherapeutic intervention. The patient continued to adjuvant tislelizumab. At the last follow-up in August 2025, the patient had a progression-free survival (PFS) of 29.8 months, with no evidence of recurrence in the lung lesions. This case demonstrates the efficacy of a multimodal induction chemoimmunotherapy in achieving complete response and preserving organ function, thereby providing a promising therapeutic option for patients with synchronous lung and base-of-tongue SCC.

26 August 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
HWHuiyun Wang
Huiyun Wang
XZXuchen Zhang
Xuchen Zhang
YTYulong Tian
Yulong Tian
HJHaitao Jiang
Haitao Jiang
NLNing Liu
Ning Liu
HHhelei hou
helei hou
The efficacy and safety of adding immune checkpoint inhibitors (ICIs) to neoadjuvant chemotherapy in patients with potentially resectable gastric cancer (GC) are uncertain. This study aimed to retrospectively evaluate the efficacy and safety of neoadjuvant ICIs plus chemotherapy in patients with potentially resectable GC. We retrospectively collected clinical data from patients with potentially resectable GC who received neoadjuvant treatment followed by gastrectomy at the Affiliated Hospital of Qingdao University from 2021 to 2023. The primary aim of this study was to investigate the differences in pathological tumor response (tumor regression grade, TRG) between neoadjuvant programmed cell death-(ligand)1 [PD-(L)1] blockade plus chemotherapy [neoadjuvant immunotherapy (IO) group] and chemotherapy alone (neoadjuvant chemotherapy group). Event-free survival (EFS) and treatment-related adverse events (TRAEs) were also observed. A total of 220 patients were retrospectively included in the analysis, among whom 96 (43.6%) received PD-(L)1 blockade plus chemotherapy as neoadjuvant treatment, and 124 (56.4%) received neoadjuvant chemotherapy. Higher pathological complete response (pCR) rate (21 of 96, 21.9% vs. 9 of 124, 7.2%, P = .004) and TRG0/1 rate (36 of 96, 37.5% vs. 22 of 124, 17.7%, P = .001) were detected in the neoadjuvant IO group. By the last follow-up, the median EFS time had not been reached in the two groups. The combined regimen of PD-(L)1 blockade plus chemotherapy was well-tolerated. In patients with potentially resectable GC, neoadjuvant ICIs plus chemotherapy resulted in higher pCR rates than did neoadjuvant chemotherapy alone. However, the difference in EFS rates was not statistically significant.